Why Affimed Stock Is On Fire Today
Shares of the German cancer immunotherapy company Affimed (NASDAQ: AFMD) jumped by as much as 25% in premarket trading Monday morning. The biotech's stock is popping in early morning action today in response to overwhelmingly positive early-stage trial results for its lead product candidate, AFM13.
Specifically, Affimed announced that an investigator-initiated phase 1/2 trial evaluating AFM13 in combination with cord blood-derived allogeneic natural killer cells produced a 100% objective response rate in patients with recurrent or refractory CD30-positive lymphomas at the recommended phase 2 dose and after a single treatment cycle. Equally important, the company noted that there were no reports of serious adverse events such as cytokine release syndrome, immune cell-associated neurotoxicity syndrome, or graft-versus-host disease.
Image source: Getty Images.
Source Fool.com
